Chemistry: natural resins or derivatives; peptides or proteins; – Peptides of 3 to 100 amino acid residues – 25 or more amino acid residues in defined sequence
Reexamination Certificate
2007-11-20
2007-11-20
Nashed, Nashaat T. (Department: 1656)
Chemistry: natural resins or derivatives; peptides or proteins;
Peptides of 3 to 100 amino acid residues
25 or more amino acid residues in defined sequence
C514S002600
Reexamination Certificate
active
11471912
ABSTRACT:
Crystalline IGF-1 is provided along with a method for production thereof. Crystallizing IGF-1 comprises the steps of mixing an aqueous solution comprising IGF-1 with a reservoir solution comprising a precipitant to form a mixture; and crystallizing the mixture, optionally also recrystallizing and isolating the crystalline IGF-1. In addition, a method for identifying IGF-1 indirect agonists is provided using a detergent as a standard for the level of inhibition of binding of IGFBP-1 or IGFBP-3 to IGF-1 and/or using the coordinates of the binding pockets of IGF-1 to which a candidate indirect agonist binds for structure-based drug design.
REFERENCES:
patent: 4672108 (1987-06-01), Kung et al.
patent: 4833233 (1989-05-01), Carter
patent: 4876242 (1989-10-01), Applebaum et al.
patent: 4959351 (1990-09-01), Grau
patent: 4988675 (1991-01-01), Froesch et al.
patent: 5028587 (1991-07-01), Dorschug et al.
patent: 5068224 (1991-11-01), Fryklund et al.
patent: 5077276 (1991-12-01), Ballard et al.
patent: 5093317 (1992-03-01), Lewis et al.
patent: 5106832 (1992-04-01), Froesch et al.
patent: 5126324 (1992-06-01), Clark et al.
patent: 5164370 (1992-11-01), Ballard et al.
patent: 5187151 (1993-02-01), Clark et al.
patent: 5202119 (1993-04-01), Clark et al.
patent: 5273961 (1993-12-01), Clark
patent: 5374620 (1994-12-01), Clark et al.
patent: 5461031 (1995-10-01), De Felippis
patent: 5466670 (1995-11-01), Dunger et al.
patent: 5470828 (1995-11-01), Ballard et al.
patent: 5504188 (1996-04-01), Baker et al.
patent: 5534488 (1996-07-01), Hoffmann
patent: 5547930 (1996-08-01), Balschmidt
patent: 5569648 (1996-10-01), Lewis et al.
patent: 5597893 (1997-01-01), Baker et al.
patent: 5650486 (1997-07-01), De Felippis
patent: 5714460 (1998-02-01), Gluckman et al.
patent: 5747642 (1998-05-01), De Felippis
patent: 5834422 (1998-11-01), Balschmidt
patent: 5840680 (1998-11-01), Balschmidt
patent: 5898028 (1999-04-01), Jensen et al.
patent: 5898067 (1999-04-01), Balschmidt et al.
patent: 5948751 (1999-09-01), Kimer et al.
patent: 5952297 (1999-09-01), De Felippis et al.
patent: 6127334 (2000-10-01), Kimer et al.
patent: 668914 (1995-08-01), None
patent: 91/03253 (1991-03-01), None
patent: WO 91/03253 (1991-03-01), None
patent: 92/11865 (1992-07-01), None
patent: WO 92/11865 (1992-07-01), None
patent: 93/08826 (1993-05-01), None
patent: WO 93/08826 (1993-05-01), None
patent: 93/23067 (1993-11-01), None
patent: 93/23071 (1993-11-01), None
patent: WO 93/23067 (1993-11-01), None
patent: WO 93/23071 (1993-11-01), None
patent: 93/25219 (1993-12-01), None
patent: WO 93/25219 (1993-12-01), None
patent: WO 94/04569 (1994-03-01), None
patent: WO 94/16722 (1994-08-01), None
patent: WO 96/01124 (1996-01-01), None
patent: WO 96/33216 (1996-10-01), None
patent: WO 97/00895 (1997-01-01), None
patent: WO 98/45427 (1998-10-01), None
patent: WO 99/01476 (1999-01-01), None
patent: WO 99/38011 (1999-07-01), None
patent: 00/23469 (2000-04-01), None
patent: WO 00/23469 (2000-04-01), None
patent: WO 01/72771 (2001-04-01), None
patent: 02/098914 (2002-12-01), None
Wiencek et al. New strategies for protein crystal growth. Ann. Rev. Biomed. Eng. 1999, 1, 505-534.
Gilliland et al. Crystallization of biological molecules for X-ray diffraction studies. Current Opinion in Structure Biology 1996, 6, 595-603.
Ke et al. Crystallization of RNA and RNA-protein complexes. Methods 34, 2004, 408-414.
Adams et al., “Structure of Rhombohedral 2 Zinc Insulin Crystals.”Nature.224: 491-495 (Nov. 1969).
Bach and Rechler., “Insulin-Like Growth Factor Binding Proteins.”Diabetes Reviews.3(1):38-61 (1995).
Baker et al., “Role of Insulin-Like Growth Factors in Embryonic and Postnatel Growth.”Cell.75:73-82 (Oct. 1993).
Ballard et al., “Does IGP-I Ever Act Through the Insulin Receptor?”The Insulin-Like Growth Factors and Their Regulatory Proteins., Baxter, eds., Amsterdam: Elsevier pp. 131-138 (1994).
Bar et al., “Tissue Localization of Perfused Endothelial Cell IGF Binding Protein is Markedly Altered B Association with IGP-I.”Endocrinology.127 (6):3243-3245 (1990).
Barinaga, M., “Neurotrophic Factors Enter the Clinic [News].”Science.264:772-774 (1994).
Baserga., “The Insulin-Like Growth Factor 1 Receptor: A Key to Tumor Growth?”Cancer Research55:249-25 (Jan. 1995).
Baxter, “Physiological Roles of IGF Binding Proteins”Modern Concepts of Insulin-like Growth Factors, Spencer, eds., Elsevier, New York pp. 371-380 (1991).
Baxter., “The Somatomedins: Insulin-Like Growth Factors.”Advances in Clinical Chemistry.25:49-115 (1986).
Bayne et al., “Structural Analogs of Human Insulin-Like Growth Factor Y with Reduced Affinity for Serum Binding Proteins and the Type 2 Insulin-Like Growth Factor Receptor.”J. Bio. Chem.263:6233-6239 (1988.
Bayne et al., “The C Region of Human Insulin-Like Growth Factor (IGF) I is Required for High Affinity Binding to the Type 1 IGF Receptor.”J. Bio. Chem.264(19):11004-11008 (1988).
Bayne et al., “The Roles of Tyrosines 24, 31, and 60 in the High Affinity Binding of Insulin-Like Grow Factor-I to the Type I Insulin-Like Growth Factor Receptor.”J. Bio. Chem.265(26):15648-15652 (Sep. 15, 1990).
Binoux, M., “Recent Data on Somatomedins (Insulin-Like Growth Factors).”Annales d'Endocrinologie(English Abstract Included) 41:157-192 (1980).
Blundell et al., “Insulin-Like Growth Factor: A Model for Tertiary Structure Accounting for Immunoreactivity and Receptor Binding.”Proc. Natl. Acad. Sci. USA75(1):180-184 (Jan. 1978).
Blundell et al., “Tertiary Structures, Receptor Binding, and Antigenicity of Insulinlike Growth Factors.”Federation Proc.42:2592-2597 (1983).
Bondy, C., “Clinical Uses of Insulin-Like Growth Factor I.”Annals of Internal Medicine.120:593-601 (1994).
Buckbinder et al., “Induction of the Growth Inhibitor IGF-Binding Protein 3 by p53.”Nature.377:646-6 (Oct. 1995).
Cascieri et al., “Mutants of Human Insulin-Like Growth Factor I with Reduced Affinity for the Type 1 Insulin-Like Growth Factor Receptor.”Biochemistry27(9):3229-3233 (May 3, 1988).
Cascieri et al., “Structural Analogs of Human Insulin-Like Growth Factor (IGF) I with Altered Affinity for Type 2 IGP Receptors.”J. Bio. Chem.264:2199-2202 (1989).
Cavanagh et al.Protein NMR Spectroscopy: Principles and Practice., New York:Academic Press, Inc. (199.
Clemmons and Van Wyk., “Somatomedin: Physiological Control and Effects on Cell Proliferation.”Handboo Exp. Pharmacol.57:161-208 (1981).
Clemmons et al., “Competition for Binding to Insulin-Like Growth Factor (IGF) Binding Protein-2, 3, 4, and 5 by the IGFs and IGF Analogs.”Endocrinology.131(2):890-895 (Aug. 1992).
Clemmons et al., “Discrete Alterations of the Insulin-Like Growth Factor I Molecule Which Alter Its Affinity for Insulin-Like Growth Factor-Binding Proteins Result in Changes in Bioactivity.”J. Bio. Chem.265(21):12210-12216 (1990).
Clemmons et al., “The Role of Insulin-Like Growth Factors in the Nervous System.”Anal. NY Acad. Sci. USA692:10-21 (1993).
Clore et al., “Stereospecific Assignment of β-Methylene Protons in Larger Proteins Using 3D15N-Separated Hartmann-Hahn and13C-Separated Rotating Frame Overhauser Spectroscopy.”J. Biomol. NMR1:13-22 (1991).
Cohen et al., “Biological Effects of Prostate Specific Antigen as an Insulin-Like Growth Factor Binding Protein-3 Protease.”J. Endocrinology.142:407-415 (1994).
Cohen et al., “Insulin-Like Growth Factors (IGFs), IGF Receptors, and IGF-Binding Proteins in Primary Cultures of Prostate Epithelial Cells.”J. Clin. Endocrin.&Metab.73:401-407 (1991).
Cohen et al., “The IGF Axis in the Prostate.”Horm.&Metab. Res.26:81-84 (1994).
Cooke et al., “Solution Structure of Human Insulin-Like Growth Factor 1: A Nuclear Magnetic Resonance and Restrained Molecular Dynamics Study”Biochemistry30:
Schaffer Michelle
Ultsch Mark
Vajdos Felix
Dreger, Esq. Ginger R.
Genentech Inc.
Hasak, Esq. Janet E.
Heller Ehrman LLP
Nashed Nashaat T.
LandOfFree
Crystallization of IGF-1 does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Crystallization of IGF-1, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Crystallization of IGF-1 will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3848303